Other Services

This Service

A database built with INDRA combining content from numerous readers and databases. This page allows you to curate the loaded statements. For more information please see the manual.

This Project

INDRA is developed by indralabs, a part of the Harvard Medical School Laboratory of Systems Pharmacology.

This project, indra_db, is also developed by the indralab team. For more information on how we procure our sources, you can go here. This work was funded by ARO grant W911NF‐15‐1‐0544 under the DARPA Communicating with Computers program.

IndraLab

Statements

N-ethylmaleimide inhibits PAN2. 1 / 1

| 1

➶

reach

"Although the conserved cysteine residue in the triad of classical DUBs is replaced by alanine (A526) in the UCH domain of USP52, we demonstrated that addition of the alkylating reagent N-ethylmaleimide (NEM), a known inhibitor of cysteine proteases XREF_BIBR, XREF_BIBR, almost completely abolished the catalytic activity of USP52 against K48- or K63 linked tetra-ubiquitins."

29599486

Our Sources:

INDRA allows us to combine the results from a multitude of sources. In particular, the INDRA Database draws on the following...